




RealRate

PHARMACEUTICAL 2020

NovaBay Pharmaceuticals Inc.
Rank 259 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2020

NovaBay Pharmaceuticals Inc.
Rank 259 of 362



The relative strengths and weaknesses of NovaBay Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NovaBay Pharmaceuticals Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 256% points. The greatest weakness of NovaBay Pharmaceuticals Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 237% points.

The company's Economic Capital Ratio, given in the ranking table, is -355%, being 52% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	9,381
Cost of Goods Sold	1,738
Intangible Assets	0
Liabilities, Current	5,687
Liabilities, Non-Current	505
Other Assets	1,729
Other Compr. Net Income	0
Other Expenses	8,024
Other Liabilities	4,055
Other Net Income	-1,001
Property and Equipment	110
Research and Development	184
Revenues	6,599
Selling, General and Administrative Expense	5,310

Output Variable	Value in 1000 USD
Assets	11,220
Liabilities	10,247
Expenses	15,256
Stockholders Equity	973
Net Income	-9,658
Comprehensive Net Income	-9,658
Economic Capital Ratio	-355%

